EGFR and colorectal carcinoma: In CRC cells (WiDr), which were exposed to treatment with a BRAF inhibitor vemurafenib [130], downregulation of the phospho-proteins MEK1/2 and ERK1/2 and upregulation in phospho-EGFR were observed, which was in line with the previously reported literature findings.